202 related articles for article (PubMed ID: 36209275)
1. HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis.
Su X; Xie Y; Zhang J; Li M; Zhang Q; Jin G; Liu F
Cell Death Dis; 2022 Oct; 13(10):861. PubMed ID: 36209275
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
3. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A
Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900
[TBL] [Abstract][Full Text] [Related]
4. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C
Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor-2α (HIF-2α), but not HIF-1α, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells.
Bordji K; Grandval A; Cuhna-Alves L; Lechapt-Zalcman E; Bernaudin M
FEBS J; 2014 Dec; 281(23):5220-36. PubMed ID: 25244496
[TBL] [Abstract][Full Text] [Related]
6. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
Eleftheriadis T; Pissas G; Mavropoulos A; Nikolaou E; Filippidis G; Liakopoulos V; Stefanidis I
Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):31. PubMed ID: 33011826
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
[TBL] [Abstract][Full Text] [Related]
8. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
Zhao W; Yun K
Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
Chang WT; Lo YC; Gao ZH; Wu SN
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
[TBL] [Abstract][Full Text] [Related]
10. Get use to the -dustats: Roxadustat and molidustat, members of the hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor drug class promote kidney function, perfusion and oxygenation in rats through nitric oxide.
Jensen BL
Acta Physiol (Oxf); 2021 Sep; 233(1):e13706. PubMed ID: 34143560
[No Abstract] [Full Text] [Related]
11. Prolyl-4-hydroxylase 2 enhances hypoxia-induced glioblastoma cell death by regulating the gene expression of hypoxia-inducible factor-α.
Sun W; Jelkmann W; Depping R
Cell Death Dis; 2014 Jul; 5(7):e1322. PubMed ID: 25010988
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
Beck J; Henschel C; Chou J; Lin A; Del Balzo U
Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
[TBL] [Abstract][Full Text] [Related]
13. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
Persano L; Pistollato F; Rampazzo E; Della Puppa A; Abbadi S; Frasson C; Volpin F; Indraccolo S; Scienza R; Basso G
Cell Death Dis; 2012 Oct; 3(10):e412. PubMed ID: 23076220
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3
Li X; Zou Y; Xing J; Fu YY; Wang KY; Wan PZ; Zhai XY
Oxid Med Cell Longev; 2020; 2020():6286984. PubMed ID: 32051732
[TBL] [Abstract][Full Text] [Related]
15. The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A.
Ike T; Doi S; Nakashima A; Sasaki K; Ishiuchi N; Asano T; Masaki T
Am J Physiol Renal Physiol; 2022 Nov; 323(5):F539-F552. PubMed ID: 36074918
[TBL] [Abstract][Full Text] [Related]
16. Correction: HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis.
Su X; Xie Y; Zhang J; Li M; Zhang Q; Jin G; Liu F
Cell Death Dis; 2023 Jan; 14(1):31. PubMed ID: 36650128
[No Abstract] [Full Text] [Related]
17. Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors.
Henze AT; Riedel J; Diem T; Wenner J; Flamme I; Pouyseggur J; Plate KH; Acker T
Cancer Res; 2010 Jan; 70(1):357-66. PubMed ID: 20028863
[TBL] [Abstract][Full Text] [Related]
18. Selective HIF stabilization alleviates hepatocellular steatosis and ballooning in a rodent model of 70% liver resection.
Iesari S; Leclercq I; Joudiou N; Komuta M; Daumerie A; Ambroise J; Dili A; Feza-Bingi N; Xhema D; Bouzin C; Gallez B; Pisani F; Bonaccorsi-Riani E; Gianello P
Clin Sci (Lond); 2021 Oct; 135(19):2285-2305. PubMed ID: 34550341
[TBL] [Abstract][Full Text] [Related]
19. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
Su K; Li Z; Yu Y; Zhang X
Drug Discov Today; 2020 Jul; 25(7):1262-1269. PubMed ID: 32380083
[TBL] [Abstract][Full Text] [Related]
20. Atypical induction of HIF-1α expression by pericellular Notch1 signaling suffices for the malignancy of glioblastoma multiforme cells.
Lee J; Kim E; Chong K; Ryu SW; Kim C; Choi K; Kim JH; Choi C
Cell Mol Life Sci; 2022 Oct; 79(10):537. PubMed ID: 36183290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
